Meeting
2021 Gastrointestinal Cancers Symposium
Analysis of early tumor shrinkage and depth of response in patients with advanced biliary tract cancer treated with gemcitabine plus cisplatin or gemcitabine plus S-1: An exploratory analysis of JCOG1113.
Authors
Naohiro Okano
Kyorin University Faculty of Medicine, Tokyo, Japan
Naohiro Okano , Chigusa Morizane , Takuji Okusaka , Ryo Sadachi , Tomoko Kataoka , Makoto Ueno , Masafumi Ikeda , Masato Ozaka , Kazuya Sugimori , Akiko Todaka , Satoshi Shimizu , Nobumasa Mizuno , Tomohisa Yamamoto , Keiji Sano , Kazutoshi Tobimatsu , Akio Katanuma , Atsushi Miyamoto , Hironori Yamaguchi , Hiroshi Ishii , Junji Furuse
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Hepatobiliary Cancer
Track
Hepatobiliary Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
UMIN000010667
Citation
J Clin Oncol 39, 2021 (suppl 3; abstr 301)
DOI
10.1200/JCO.2021.39.3_suppl.301
Abstract #
301
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Sintilimab plus gemcitabine and cisplatin as a first-line treatment for patients with advanced biliary tract cancer: A biomolecular exploratory, phase II clinical trial.
First Author: Zhen-gang Yuan
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Outcomes by antibiotic use in participants with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase 3 TOPAZ-1 study.
First Author: Aiwu He
Poster
2022 ASCO Gastrointestinal Cancers Symposium
The influence of major hepatectomy on gemcitabine-based chemotherapy for advanced biliary tract cancer: An exploratory subset analysis of JCOG1113.
First Author: Tatsuya Okuno
Poster
2021 ASCO Annual Meeting
A multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin with or without CPI-613 as first-line therapy for patients with advanced unresectable biliary tract cancer (BilT-04).
First Author: Vaibhav Sahai